BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 24813594)

  • 1. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae.
    Harada Y; Morinaga Y; Kaku N; Nakamura S; Uno N; Hasegawa H; Izumikawa K; Kohno S; Yanagihara K
    Clin Microbiol Infect; 2014 Nov; 20(11):O831-9. PubMed ID: 24813594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
    Burgess DS; Hall RG
    Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
    Raveh D; Yinnon AM; Broide E; Rudensky B
    Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Thomson KS; Moland ES
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
    DeRyke CA; Banevicius MA; Fan HW; Nicolau DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
    Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates.
    Pillay T; Pillay DG; Adhikari M; Sturm AW
    Am J Perinatol; 1998 Jan; 15(1):47-51. PubMed ID: 9475688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
    Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
    JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
    Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
    J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacies of ceftazidime and cefepime in rats with experimental pneumonia caused by extended-spectrum beta-lactamase-producing strain of Klebsiella pneumonia].
    Wang WF; Liu YN; She DY
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Jun; 29(6):390-4. PubMed ID: 17045021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
    Bulik CC; Tessier PR; Keel RA; Sutherland CA; Nicolau DP
    Antimicrob Agents Chemother; 2012 Jan; 56(1):544-9. PubMed ID: 22064538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014.
    Sader HS; Castanheira M; Mendes RE; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro activity of piperacillin-tazobactam against Klebsiella pneumoniae clinical isolates, producers or not of extended spectrum beta-lactamases].
    Alarcón T; de la Obra P; López-Hernandez S; de las Cuevas C; López-Brea M
    Rev Esp Quimioter; 1999 Sep; 12(3):229-33. PubMed ID: 10878513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of two penicillins plus beta-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections.
    Fournier JL; Ramisse F; Jacolot AC; Szatanik M; Petitjean OJ; Alonso JM; Scavizzi MR
    Antimicrob Agents Chemother; 1996 Feb; 40(2):325-30. PubMed ID: 8834874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
    Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
    Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility.
    Zimhony O; Chmelnitsky I; Bardenstein R; Goland S; Hammer Muntz O; Navon Venezia S; Carmeli Y
    Antimicrob Agents Chemother; 2006 Sep; 50(9):3179-82. PubMed ID: 16940124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniae murine pneumonia model.
    Hilliard JJ; Melton JL; Hall L; Abbanat D; Fernandez J; Ward CK; Bunting RA; Barron A; Lynch AS; Flamm RK
    Antimicrob Agents Chemother; 2011 Feb; 55(2):836-44. PubMed ID: 21135187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
    Han SB; Jung SW; Bae EY; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH; Kim HK; Park YJ
    Microb Drug Resist; 2015 Apr; 21(2):244-51. PubMed ID: 25398058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
    Liu HC; Hung YP; Lin HJ; Liu HC; Lee JC; Wu YH; Li CW; Li MC; Ko WC
    J Microbiol Immunol Infect; 2016 Aug; 49(4):584-90. PubMed ID: 26692184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.